Regulatory FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia FDAThe U.S.NeuroscienceRead full story pharminent April 30, 2026 (Last updated: May 1, 2026) FDA The U.S. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eligibility for Medicare Savings Programs for Specified Low-Income Medicare Beneficiaries (SLMBs)Next: Two biotechs raise a combined $556M in latest spurt of IPOs Related Stories Regulatory Japan approves Sanofi’s Sarclisa combo for MM treatment pharminent June 22, 2026 Regulatory FDA experts endorse Moderna’s mRNA seasonal flu shot pharminent June 19, 2026 Regulatory Moderna flu vaccine wins unanimous support from FDA panel pharminent June 18, 2026
